Strategic definition
Concept, proposed location and initial dossier.
Completed / consolidatingBarra do Dande · Angola
From molecule
to market.Industrial capability.
KAIROS Global Pharma is structuring an integrated platform to manufacture essential medicines, develop advanced nutraceuticals and build technical capability in Angola.
Official masterplanKAIROS Global Pharma CampusConceptual representation subject to engineering development.
Subtle masterplan motion
10 haTotal site area
12,600 m²Covered area — Phase 1
USD 44.4mEstimated pre-FEED investment
86Direct jobs — Phase 1
300K → 1MBottles/month — Nutra capacity
SADC+Priority target markets
01 / THESIS
What KAIROS is
A platform connecting manufacturing, quality, energy, data, talent and market access.
The concept brings together two engines — Pharma and NutraTech — with shared infrastructure, laboratories, utilities, logistics and technical training.
The final configuration will be closed through independent engineering, commercial validation, competitive procurement and stage-gate decisions.
Industrial system
Two engines.
One architecture.
Pharma addresses local and regional manufacturing. NutraTech seeks to create export capability, but remains the main area requiring commercial and physical validation.
01 · Pharma
Essential medicines.
Local manufacturing with GMP discipline.
01
Proposed initial portfolio
Paracetamol, Amoxicillin, Metronidazole, Ibuprofen and Saline — subject to final definition, registration and capacity.
02
Priority market
Angola, with regional expansion subject to demand, licences and qualification.
03
Implementation principle
Phase complexity and prevent the sterile component from compromising the first operation.
Differentiated products, mandatory commercial proof.
01
Five initial concepts
Formulations associated with performance, gut health, cognition, immunity and women’s health.
02
Development scale
Initial target of 300,000 bottles/month and scale-up to 1 million/month, still subject to line balance and CAPEX.
03
Investment condition
Net price, channel, distributors, formulas, certification and capacity must be evidenced.
Numbers with context
The scale is clear.
So is the nature of each number.
The editorial system avoids presenting estimates and targets as completed facts. That distinction is a credibility tool.
01
Site area
10 ha
Documented basis02
Proposed covered area
12.600 m²
Current concept03
Current CAPEX
USD 44,415 M
Pre-FEED estimate04
Phase 1 direct employment
86
Promoter forecast05
Nutra scale capacity
1M frascos/mês
Target to validateProject anatomy
The project can be read.
Zone by zone.
The public masterplan is conceptual. Final design depends on topography, geotechnical work, utilities, GMP flows, FEED and competent-authority approvals.
Investment discipline
Capital should only follow evidence.
The thesis is not to build everything immediately. Capital is released as engineering, market, regulatory and financing evidence passes defined gates.
USD 44.415M
Current Phase 1 estimate. It is not a construction budget or financing commitment. It must be replaced by a Basis of Estimate supported by FEED and quotations.
Founder equity
71%
Target leasing
20%
Target incentives
9%
Development status
Knowing where we are is part of the project.
Transparency about maturity increases trust. The project is not yet ready for full construction.
Development basis
Leadership, commercial validation, studies and FEED.
Current stageDesign and contracting
BoE, licences, contracts and financing.
PendingConstruction
Controlled execution, quality and change control.
Not startedQualification and launch
Validation, authorisations, manufacturing and market release.
FutureWe are not selling a completed factory. We are building an industrial capability that must be proven.
Institutional access
Detailed information for qualified parties.
The public website explains the project. The institutional portal should make models, reports, risk, engineering, documents and evidence available under controlled access.